Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta

European Journal of Human Genetics

Volumn 22, Issue 5, 2014, Pages 667-674

  Rousseau, Julie ^a,b   Gioia, Roberta ^c   Layrolle, Pierre ^a,b   Lieubeau, Blandine ^b,d   Heymann, Dominique ^a,b   Rossi, Antonio ^c   Marini, Joan C ^e   Trichet, Valerie ^a,b   Forlino, Antonella ^c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITY OF PAVIA   (Italy)

^d CEMAGREF   (France)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

allele specific Col1a1 silencing; lentiviral vector; osteogenesis imperfecta; shRNA; siRNA

Indexed keywords

COL1A1 PROTEIN; COLLAGEN TYPE 1; DIMER; FIREFLY LUCIFERASE; HEAT SHOCK PROTEIN 47; LENTIVIRUS VECTOR; MUTANT PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; COLLAGEN TYPE I, ALPHA 1 CHAIN;

3' UNTRANSLATED REGION; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; EX VIVO STUDY; FIBROBLAST; FLOW CYTOMETRY; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MOUSE; NEWBORN; NONHUMAN; NONVIRAL GENE THERAPY; OPEN READING FRAME; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; WILD TYPE; ANIMAL; CELL LINE; DISEASE MODEL; EXON; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MUTATION; RNA INTERFERENCE;

LENTIVIRUS;

ALLELES; ANIMALS; CELL LINE; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; EXONS; FIBROBLASTS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; MICE; MICE, KNOCKOUT; MUTATION; OSTEOGENESIS IMPERFECTA; PROTEIN BIOSYNTHESIS; RNA INTERFERENCE;

EID: 84898835680     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.198     Document Type: Article

References (46)

1. Miller VM, Xia H, Marrs GL et al: Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003; 100: 7195-7200.
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
3. Hamilton AJ, Baulcombe DC: A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999; 286: 950-952.
4. Ding H, Schwarz DS, Keene A et al: Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003; 2: 209-217.
5. Millington-Ward S, McMahon HP, Allen D et al: RNAi of COL1A1 in mesenchymal progenitor cells. Eur J Hum Genet 2004; 12: 864-866.
6. Lindahl K, Rubin CJ, Kindmark A, Ljunggren O: Allele dependent silencing of COL1A2 using small interfering RNAs. Int J Med Sci 2008; 5: 361-365.
7. Klootwijk RD, Savelkoul PJ, Ciccone C et al: Allele-specific silencing of the dominant disease allele in sialuria by RNA interference. Faseb J 2008; 22: 3846-3852.
8. Loy RE, Lueck JD, Mostajo-Radji MA, Carrell EM, Dirksen RT: Allele-specific gene silencing in two mouse models of autosomal dominant skeletal myopathy. PLoS One 2012; 7: e49757.
9. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
10. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16: 948-958.
11. Forlino A, Cabral WA, Barnes AM, Marini JC: New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 2011; 7: 540-557.
12. Marini JC, Forlino A, Cabral WA et al: Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007; 28: 209-221.
13. Monti E, Mottes M, Fraschini P et al: Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag 2010; 6: 367-381.
14. Cheung MS, Glorieux FH: Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord 2008; 9: 153-160.
15. Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM: Sclerostin antibody improves skeletal parameters in a Brtl/ mouse model of osteogenesis imperfecta. J Bone Miner Res 2013; 28: 73-80.
16. Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E: First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 2012; 12: 183-188.
17. Sillence DO, Senn A, Danks DM: Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101-116.
18. Li F, Wang X, Niyibizi C: Distribution of single-cell expanded marrow derived progenitors in a developing mouse model of osteogenesis imperfecta following systemic transplantation. Stem Cells 2007; 25: 3183-3193.
19. Guillot PV, Abass O, Bassett JH et al: Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood 2008; 111: 1717-1725.
20. Panaroni C, Gioia R, Lupi A et al: In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood 2009; 114: 459-468.
21. Horwitz EM, Prockop DJ, Gordon PL et al: Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97: 1227-1231.
22. Le Blanc K, Gotherstrom C, Ringden O et al: Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005; 79: 1607-1614.
23. Prockop DJ, Brenner M, Fibbe WE et al: Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010; 12: 576-578.
24. Jackson AL, Bartz SR, Schelter J et al: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21: 635-637.
25. Forlino A, Porter FD, Lee EJ, Westphal H, Marini JC: Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice. J Biol Chem 1999; 274: 37923-37931.
26. Chang JT: An economic and efficient method of RNAi vector constructions. Anal Biochem 2004; 334: 199-200.
27. Rousseau J, Escriou V, Perrot P et al: Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther 2010; 17: 387-397.
28. Qin XF, An DS, Chen IS, Baltimore D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-188.
29. Chipoy C, Brounais B, Trichet V et al: Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene 2007; 26: 6653-6664.
30. Forlino A, Tani C, Rossi A et al: Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics 2007; 7: 1877-1891.
31. Forlino A, Kuznetsova NV, Marini JC, Leikin S: Selective retention and degradation of molecules with a single mutant alpha1(I) chain in the Brtl IV mouse model of OI. Matrix Biol 2007; 26: 604-614.
32. Gioia R, Panaroni C, Besio R et al: Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells 2012; 30: 1465-1476.
33. Grassi G, Forlino A, Marini JC: Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects. Nucleic Acids Res 1997; 25: 3451-3458.
34. Cabral WA, Marini JC: High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am J Hum Genet 2004; 74: 752-760.
35. Wang Q, Marini JC: Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest 1996; 97: 448-454.
36. Dawson PA, Marini JC: Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts. Nucleic Acids Res 2000; 28: 4013-4020.
37. Rettig GR, Behlke MA: Progress toward in vivo use of siRNAs-II. Mol Ther 2012; 20: 483-512.
38. Schwarz DS, Ding H, Kennington L et al: Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2006; 2: e140.
39. Ohnishi Y, Tamura Y, Yoshida M, Tokunaga K, Hohjoh H: Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PLoS One 2008; 3: e2248.
40. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115: 199-208.
41. Bumcrot D, Manoharan M, Koteliansky V, Sah DW: RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2: 711-719.
42. Tsang KY, Chan D, Bateman JF, Cheah KS: In vivo cellular adaptation to ER stress: survival strategies with double-edged consequences. J Cell Sci 2010; 123: 2145-2154.
43. Kojima T, Miyaishi O, Saga S, Ishiguro N, Tsutsui Y, Iwata H: The retention of abnormal type I procollagen and correlated expression of HSP 47 in fibroblasts from a patient with lethal osteogenesis imperfecta. J Pathol 1998; 184: 212-218.
44. Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al: Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823.
45. Biffi A, Bartolomae CC, Cesana D et al: Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011; 117: 5332-5339.
46. Perez-Pinera P, Ousterout DG, Brown MT, Gersbach CA: Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases. Nucleic Acids Res 2012; 40: 3741-3752.